Background Adenosine has been proposed to be an important mediator of ischemic preconditioning. Intracoronary administration of adenosine has recently been shown to mimic the effects of preconditioning in isolated rabbit hearts. However, it is not known whether this agent can duplicate the effects of preconditioning in vivo or in other species. Thus, the first objective of the present study was to determine whether adenosine can limit myocardial necrosis to the same extent as preconditioning in anesthetized dogs. A second objective was to determine whether the duration of the adenosine-induced cardioprotection persisted as long as that of ischemic preconditioning. Finally, a third aim was to determine whether adenosine mediates its cardioprotection via the KAT channel,
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Background Adenosine has been proposed to be an important mediator of ischemic preconditioning. Intracoronary administration of adenosine has recently been shown to mimic the effects of preconditioning in isolated rabbit hearts. However, it is not known whether this agent can duplicate the effects of preconditioning in vivo or in other species. Thus, the first objective of the present study was to determine whether adenosine can limit myocardial necrosis to the same extent as preconditioning in anesthetized dogs. A second objective was to determine whether the duration of the adenosine-induced cardioprotection persisted as long as that of ischemic preconditioning. Finally, a third aim was to determine whether adenosine mediates its cardioprotection via the KAT channel, which has been shown to be an important mediator of preconditioning in several animal species, including dogs. Methods and Results Barbital-anesthetized open-chest dogs were subjected to 60 minutes of left anterior descending coronary artery (LAD) occlusion followed by 4 hours of reperfusion. Preconditioning was elicited by 10 minutes of LAD occlusion followed by 10 or 60 minutes of reperfusion before the 60-minute occlusion period. Adenosine (400 ,.g/ min) or an equivalent volume of saline was infused into the LAD for 10 minutes, followed by a 10-or 60-minute drug-free period before the 60-minute ischemic insult. Glibenclamide (0.3 mg/kg IV), a selective KATP channel blocker, was given 15 minutes before adenosine administration, and another selective KATP channel blocker, 5-hydroxydecanoate (5-HD, 3 mg/ min IC) was infused concomitantly with adenosine into the LAD for 10 minutes. Transmural myocardial blood flow was measured at 5 minutes of occlusion, and infarct size was determined by triphenyltetrazolium staining and expressed as a percent of the area at risk (AAR). There were no significant differences in hemodynamics, collateral blood flow, or AAR between groups. Preconditioning with either 10 or 60 minutes of reperfusion produced a marked reduction (P<.05) in infarct size (6.7±2.5% and 8.7±2.6%, respectively, versus 26.9±4.3% in controls). Administration of adenosine with a 10-minute drug-free period before 60 minutes of occlusion resulted in a marked decrease in infarct size similar to that seen with preconditioning (9.6±1.7% versus 26.9±4.3% in controls); however, the protection disappeared when a 60-minute drugfree period was allowed after adenosine administration (23 Adenosine is a metabolite of adenine nucleotides; it accumulates quickly in large amounts in the ischemic myocardium.4 A large body of evidence suggests that adenosine can protect the heart against ischemia/reperfusion injury.5 Numerous recent studies have shown that activation of adenosine A, receptors mimicked and blockade of these receptors abolished the effect of ischemic preconditioning to reduce infarct size. 5 Liu and coworkers6 have further demonstrated that in isolated blood-perfused rabbit hearts, intracoronary infusion of adenosine for 5 minutes followed by 10 beats per minute, the heart was paced at that rate with rectangular pulses of 4-millisecond duration and a voltage twice threshold via bipolar electrodes sutured to the left atrial appendage. Pacing was not used in the few animals with initial rates > 150 beats per minute, and if the rate exceeded 160 beats per minute, the animals were excluded. In this way, we attempted to control the oxygen demand at approximately the same level in all animals. Heart rate, hemodynamics, and LAD blood flow were monitored and recorded by a polygraph (model 7, Grass Instrument Co, Quincy, Mass) throughout the experiment. The left atrial appendage was cannulated for radioactive microsphere injection and the right femoral artery cannulated for withdrawal of a reference blood flow sample used for measurement of myocardial tissue blood flow. The right femoral vein was cannulated for drug administration. A small catheter with a 30-gauge needle bent at 900 was inserted into the LAD distal to the flow probe and occluder for intracoronary drug infusions.
Chemicals
Adenosine and glibenclamide were purchased from Sigma, and 5-HD was generously supplied by Dr Icilio Cavero from Rhone-Poulenc Rorer, France. Adenosine and 5-HD were freshly dissolved in saline, and the dose of glibenclamide for each dog was dissolved in 0.5 mL propylene glycol, 0.5 mL ethanol, and 0.5 mL IN NaOH before administration.
Experimental Design
Seven groups of animals were studied to determine whether adenosine can limit myocardial necrosis to an extent similar to preconditioning, whether the adenosine-induced cardioprotection persists as long as that of ischemic preconditioning, and whether adenosine mediates its cardioprotection via activating KATP channels (Fig 1) . Dogs in nonpreconditioned groups (series 1, 3, 4, 5, 7) were subjected to 60 minutes of LAD occlusion followed by 4 hours of reperfusion, whereas preconditioned dogs (series 2 and 6) received a single 10-minute occlusion followed by 10 or 60 minutes of reperfusion before being subjected to the same protocol as used in nonpreconditioned groups. In nonpreconditioned dogs (series 1, 3, 4, 5, 7), saline (series 1), adenosine (400 gg/min, series 3 and 7), 5-HD (3 mg/min) + adenosine (series 5), and glibenclamide (0.3 mg/kg) + adenosine (series 6) were infused into the LAD at a rate of 1 mL/min for 10 minutes instead of the 10-minute occlusion period used in preconditioned dogs with the exception of glibenclamide, which was given intravenously 15 minutes before adenosine administration. Doses of adenosine, glibenclamide, and 5-HD were chosen on the basis of previous studies from this laboratory.8
Infarct Size Determination
After 4 hours of reperfusion, the LAD was reoccluded and cannulated just distal to the occlusion site. Subsequently, 10 mL of saline and 10 mL of patent blue dye were injected at equal pressures into the LAD and left atrium, respectively, to determine the anatomic area at risk (AAR) and the nonischemic area. The heart was then immediately fibrillated, removed, and sliced into serial transverse sections 6 to 7 mm in width. The nonstained ischemic area was separated from the blue-stained normal area, and the two regions were incubated 7/IIIIIIZ1 reducing infarct size and to study the role of ATP-dependent potassium channels in the mechanism of adenosine-induced cardioprotection. Bottom, experimental protocol used to determine whether adenosine-induced protection persists as long as that of ischemic preconditioning. Nonpreconditioned animals (series 1, 3 through 5, and 7) were subjected to 60 minutes of left anterior descending coronary artery (LAD) occlusion (Occ) followed by 4 hours of reperfusion (Rep). Preconditioned animals (series 2 and 6) were subjected to one 1 0-minute episode of LAD occlusion followed by a 10-or 60-minute period of reperfusion before a 60-minute occlusion period. Via intracoronary infusion into the LAD, nonpreconditioned dogs received either saline (series 1) or 400 gg/min of adenosine followed by a 10-or 60-minute drug-free period (series 3 and 7). 5-Hydroxydecanoate (5-HD) (3 mg/min) + adenosine IC (series 4) were infused into the LAD for 10 minutes, followed by a 10-minute drug-free period before the 60-minute occlusion period. Finally, glibenclamide (0.3 mg/kg IV) was administered 15 minutes before intracoronary adenosine infusion (series 5).
AAR were carefully separated and weighed. Infarct size (IS) was expressed as a percent of the area at risk (IS/AAR).
Regional Myocardial Blood Flow Measurement
Regional myocardial tissue blood flow of the normal and ischemic regions was measured by the radioactive microsphere technique as previously described in this laboratory. 10 
Criteria for Exclusion
To ensure that all animals included in data analysis were healthy and exposed to a similar extent of ischemia, the following criteria were used to exclude unsatisfactory dogs: (1) subendocardial collateral flow >0.15 mL min-1 . g-'; (2) heart rate >160 beats per minute; and (3) more than three consecutive attempts required to convert ventricular fibrillation with low-energy DC pulses applied directly to the heart.
Statistical Analysis
All values are expressed as mean +±SEM. Differences between groups in hemodynamics, blood gases and pH, myocardial blood flow, and infarct size were compared by a two-factor ANOVA with repeated measures and Fisher's least significant difference test. Linear regression analysis was also performed to determine the relation between transmural collateral blood flow and infarct size expressed as a percent of the AAR. Differences in regression lines between groups were compared by ANCOVA. Differences between groups were considered significant at P<.05.
Results

Mortality and Exclusions
A total of 58 dogs were randomly assigned to one of seven groups: control (group 1), preconditioned with 10 minutes or 60 minutes of reperfusion (groups 2 and 6), adenosine-treated with 10 minutes or 60 minutes drug free (groups 3 and 7), 5-HD + adenosine (group 4), and glibenclamide + adenosine (group 5). Five dogs were excluded because subendocardial collateral blood flow was >0.15 mL min'1 g`1 (1 each in groups 1, 2, and 4; 2 in group 3). Thus, 53 dogs completed the protocol satisfactorily and were used in data analysis (n=12 for the control group, n=9 for the preconditioned group with 10 minutes of reperfusion, n=8 for adenosinetreated with a 10-minute drug-free period, and n=6 for the other four groups). Hemodynamics Heart rate, mean aortic blood pressure, the ratepressure product, left ventricular dP/dt, and LAD coronary arterial blood flow were monitored throughout the experiment; the baseline values for all series are summarized in Table 1 . Hemodynamics were not significantly different among groups throughout the experiment except that LAD blood flow during the 10 minutes of drug infusion was markedly higher in groups treated with either adenosine (400 ,ug/min, 115+±-16 mL/min), 5 -HD + adenosine (115 ± 17 mL/min), or glibenclamide + adenosine (108±12 mL/min) than in the nonpreconditioned saline-treated controls (36±5 mL/min). The increase in LAD coronary blood flow produced by 400 gg/min of adenosine infusion (77±12 mL/min) was not Fig 2) . Fig 3 demonstrates the relation between infarct size (IS/AAR) and transmural collateral blood flow to the ischemic region at 5 minutes of occlusion. An inverse relation was found between these two parameters in all groups. The regression lines in the preconditioned group and the group treated with adenosine were shifted downward and had a flatter slope (Fig 3) . The lines for the groups treated with 5-HD plus adenosine or glibenclamide + adenosine (Fig 3C and 3D) were shifted back like those observed in the nonpreconditioned saline-treated control group. These results indicate that at any given transmural collateral flow, infarct size would be expected to be smaller in the preconditioned group and the adenosine-treated group. Preconditioning with 60 minutes of reperfusion (PRE, n=6) produced a significant reduction in infarct size, whereas adenosine with a 60-minute drug-free period (ADO, n=6) did not affect the infarct size compared with the nonpreconditioned control group (CONT, n=12). These results indicate that the protection afforded by preconditioning persisted for at least 1 hour; however, adenosine-induced protection totally disappeared within 1 hour.
Fig 4 shows that preconditioning with 60 minutes of reperfusion, like that with 10 minutes of reperfusion (6.7±2.5%), resulted in a marked reduction in infarct size (8.7±2.6%); however, adenosine with a 60-minute drug-free period had no effect on infarct size (23.0±2.4% versus 26.9±4.3% in controls). Fig 5A  reveals that the regression line in the preconditioned group with 60 minutes of reperfusion, like that with 10 minutes of reperfusion, was shifted downward and had a flatter slope. In contrast, the line in the group treated with adenosine followed by a 60-minute drug-free period was shifted back to that in the nonpreconditioned saline-treated control group (Fig 5B) . These results indicate that the protection afforded by preconditioning persisted at least for 1 hour; however, adenosine-induced protection totally disappeared within 1 hour.
Regional Myocardial Blood Flow
Transmural myocardial blood flow data in the ischemic (LAD) region are shown in Table 2 . There were no significant differences between groups in blood flow to any layer of the ischemic myocardium at 5 and 30 minutes of occlusion and at the end of 4 hours of reperfusion. These data indicate that all groups of animals were subjected to equivalent degrees of ischemia. No significant differences were observed among groups in the nonischemic region. reduction in infarct size was observed in a canine model of ischemic preconditioning similar to that used in the present study. Subsequently, we observed that intracoronary infusion of adenosine for 10 minutes followed by 10 minutes of recovery markedly reduced infarct size (8.6±1.9%), to the same extent as preconditioning (6.7±2.5%). In agreement, Liu et a16 showed that in isolated blood-perfused rabbit hearts, adenosine reduced myocardial infarct size to the same extent as did ischemic preconditioning. Miura et al16 found that dipyridamole, an adenosine uptake inhibitor,17 decreased the threshold for preconditioning in rabbit hearts. A recent study performed by Auchampach and Gross8 showed that in canine hearts, intracoronary infusion of a low or high dose of adenosine or a low dose of dipyridamole over a 5-minute period before a prolonged 60-minute occlusion period did not mimic preconditioning; however, intracoronary infusion of a combination of adenosine and dipyridamole produced a significant reduction in infarct size. Based on the results of that previous study with adenosine in our laboratory and the present results, it appears that 5 minutes of 400
,ug/min adenosine is insufficient to reach a high enough interstitial concentration to mimic ischemic preconditioning, whereas a 10-minute infusion is sufficient in the canine heart. The present results together with those of n . Despite the efficacy of adenosine in mimicking the effects of preconditioning, its protective effects did not persist as long as those of preconditioning. In the present experiments, it was found that the adenosineinduced cardioprotection totally disappeared 60 minutes after drug administration (23.0±2.4% versus 26.9±4.3% in controls), whereas ischemic preconditioning persisted more than 1 hour (8.7±2.6% versus 26.9±4.3% in controls). This observation suggests that the dose of adenosine administered exogenously in the present study may not be high enough to achieve an interstitial concentration comparable to that obtained during 10 minutes of preconditioning ischemia. Previous results obtained by Auchampach and Gross8 demonstrating that adenosine mimicked ischemic preconditioning only in the presence of dipyridamole, an adenosine uptake inhibitor, agree with the present findings. Alternatively, the present results suggest that other cellular mechanisms or factors in addition to adenosine may also be involved in mediating the phenomenon of preconditioning.
Conclusions
The results of the present study clearly reveal that (1) a 10-minute intracoronary infusion of adenosine is as effective as ischemic preconditioning in reducing myocardial necrosis in dogs; (2) adenosine, like preconditioning, may produce its protection via an adenosine A1 receptor-KATp channel-linked mechanism; and (3) adenosine-induced cardioprotection is transient, whereas ischemic preconditioning persists for at least an hour. These data support the hypothesis that endogenous adenosine released during ischemia is an important trigger or mediator of ischemic preconditioning and also suggest that multiple complex mechanisms must be involved in producing this endogenous cardioprotective phenomenon.
